Clinical trials: Sunitinib
Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum
Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor
Ovarian cancer is most often recognized in advanced clinical state, the initial therapeutic strategies consist of a platinum containing chemotherapy subsequent to primary surgery.
- Conditions
- Platinum Refractory Epithelial Ovarian Cancer, Primary Cancer of the Peritoneum, Cancer of the Fallopian Tube
- Trial name
- NCT00543049
- Testing
- Sunitinib
- Where
- 16 sites in Germany
- Volunteers
- 73 people
- Sponsor
- AGO Study Group
Metastatic Melanoma
Clinical Trial of Sutent to Treat Metastatic Melanoma
The purpose of this study is to investigate whether an investigational drug called sunitinib malate is safe and effective in treating metastatic melanoma in patients with KIT mutations.
- Trial name
- NCT00631618
- Testing
- Sutent (sunitinib)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- California Pacific Medical Center Research Institute
Unspecified Adult Solid Tumor, Protocol Specific
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
This phase I trial is studying the side effects and best dose of bevacizumab and sunitinib in treating patients with solid tumors. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00357318
- Testing
- sunitinib malate, bevacizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib and gemcitabine in treating patients with pancreatic cancer or other solid tumors.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00462553
- Testing
- sunitinib malate, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cancer, GIST
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
This study is a Phase I trial in two parts. In part 1, a MTD to the combination of perifosine and sunitinib malate will be determined.
- Trial name
- NCT00399152
- Testing
- Perifosine, Sunitinib Malate
- Volunteers
- 15 people
- Sponsor
- AEterna Zentaris
Carcinoma, Renal Cell
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
The purpose of this study is to evaluate efficacy and safety of Radiofrequency ablation in metastatic renal cell carcinoma patients with primary tumor less than 5 cm before medical treatment.
- Trial name
- NCT00891475
- Testing
- Radiofrequency ablation; Interferon-alpha, Radiofrequency ablation; Sunitinib maleate, Sunitinib maleate
- Where
- Russia
- Volunteers
- 114 people
- Sponsor
- Kidney Cancer Research Bureau
Neoplasms, Renal Cell Carcinoma
Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland
Patient receiving sunitinib according the clinician's independent decision as first-line treatment of advanced renal cell carcinoma (RCC) will be asked for informed consent.
- Trial name
- NCT00980213
- Testing
- sunitinib
- Where
- 5 sites in Finland
- Volunteers
- 80 people
- Sponsor
- Pirkko-Liisa Kellokumpu-Lehtinen
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma
Sunitinib in Treating Young Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors.
- Conditions
- Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00387920
- Testing
- sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging
- Where
- 17 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Intraocular Melanoma
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00489944
- Testing
- cisplatin, sunitinib malate, tamoxifen citrate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- San Diego Pacific Oncology & Hematology Associates
Kidney Cancer
Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00717587
- Testing
- motexafin gadolinium, sunitinib malate, comparative genomic hybridization
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Tumors
Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy
There are two drugs involved in this study. Sunitinib (Sutent(R)) is approved by the Food and Drug Administration (FDA) for the treatment of advanced renal cell (kidney) cancer and gastrointestinal stromal tumors.
- Trial name
- NCT00402415
- Testing
- Sunitinib malate, Rapamycin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Yale University
Nausea, Vomiting
Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting
This study will determine if giving Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)orally will be effective as a prophylactic anti-emetic drug for patients who underwent arthroscopic rotator cuff repair under general anesthesia.
- Trial name
- NCT01984931
- Testing
- Trimebutine Maleate (NEWBUTIN SR 300 mg Tab), Metoclopramide hydrochloride monohydrate
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- CM Chungmu Hospital
Carcinoma, Non-Small Cell Lung
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.
- Trial name
- NCT00457392
- Testing
- erlotinib, sunitinib
- Where
- 204 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Pfizer
Prostatic Neoplasms, Neoplasms, Hormone-Dependent
An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer
as second-line treatment in metastatic prostate cancer, the present study will investigate the efficacy of sunitinib (SUTENT) given orally at a dose of 37.5 mg continuously, for 6 cycles of 6 consecutive weeks .Patients who are…
- Conditions
- Prostatic Neoplasms, Neoplasms, Hormone-Dependent, Tumor Markers, Biological, Survival Rate
- Trial name
- PROSUT (NCT00748358)
- Testing
- sunitinib
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Kidney Cancer
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00626509
- Testing
- sunitinib malate, adjuvant therapy, neoadjuvant therapy
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Gruppo Italiano Carcinoma Renale
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
Kidney Cancer
Sunitinib Malate Before and After Surgery in Treating Patients With Previously Untreated Metastatic Kidney Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01024205
- Testing
- sunitinib malate, laboratory biomarker analysis, adjuvant therapy
- Where
- United Kingdom
- Volunteers
- 43 people
- Sponsor
- Barts and the London School of Medicine and Dentistry
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01118039
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 4 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Hospital del Mar
Renal Cell Carcinoma
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment
Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.
- Trial name
- NCT00678119
- Testing
- AGS-003, Sunitinib
- Where
- 14 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Argos Therapeutics
Metastatic Renal Cell Carcinoma
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in…
- Trial name
- NCT01073644
- Testing
- Sunitinib malate
- Where
- 2 sites in Philippines
- Volunteers
- 3 people
- Sponsor
- Pfizer